Patents Assigned to Institut Curie
  • Publication number: 20240033366
    Abstract: Modified monomers of a Shiga toxin B-subunit (STxB) protein including at least one of: an addition of a reactive unnatural amino acid residue at the C-terminal extremity, and/or a substitution with a reactive unnatural amino acid residue at an amino acid position among Asp 3, Lys 8, Glu 10, Tyr 11, Lys 23, Lys 27, Thr 49, Lys 53, His 58, Asn 59, and Arg 69, reference made to the numbering of STxB from Shigella dysenteriae. Also relates to STxB conjugates, and oligomers, in particular pentamers, of these modified STxB proteins and STxB conjugates; as well as to compositions including the same and their use in treatment, vaccination and diagnosis methods.
    Type: Application
    Filed: December 2, 2021
    Publication date: February 1, 2024
    Applicants: INSTITUT CURIE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COMMISSARIAT À L’ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (CEA), UNIVERSITE PARIS CITE, APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS)
    Inventors: Ludger JOHANNES, Anne BILLET, Jonathan ULMER, Denis SERVENT, Gilles MOURIER, Pascal KESSLER, Eric TARTOUR
  • Publication number: 20240018197
    Abstract: A hook fusion protein, which includes a hook domain and at least one cytoplasmic carboxyl endoplasmic reticulum (ER) retention signal and/or at least one cytoplasmic amino terminal endoplasmic reticulum (ER) retention signal; wherein the hook fusion protein is a soluble protein that localizes in the cytoplasm. Also, a nucleic acid system for intracellular targeting control including a nucleic acid encoding a target fusion protein including a hook fusion protein, and a nucleic acid encoding a target fusion protein including a hook-binding domain; wherein the target fusion protein is a membrane protein; and wherein the hook fusion protein localizes in the ER when bound to the target fusion protein. Additionally, a vector system, viral particle system, host cell and kit include these nucleic acids. Further, the vector system, viral particle system, host cell or kit for use as a medicament, in particular for immunotherapy.
    Type: Application
    Filed: September 11, 2023
    Publication date: January 18, 2024
    Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Franck PEREZ, Zelia GOUVEIA, Gaelle BONCOMPAIN
  • Patent number: 11866484
    Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: January 9, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT CURIE, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
  • Publication number: 20240002776
    Abstract: The present invention relates to a device (2) for providing a liquid medium with a controlled flow rate and with a controlled concentration of a dissolved gas, the device (2) comprising: —a liquid reservoir (4) provided with: —at least one gas inlet (7); —at least one gas outlet (8); and—at least one liquid outlet (9); —an admission line (5) configured to provide a gaseous medium into the liquid reservoir (4), the admission line (5) being connected to the at least one gas inlet (7) and comprising at least one control valve (12); and an emission line (6) configured to withdraw the gaseous medium from the liquid reservoir (4), the emission line (6) being connected to the at least one gas outlet (8) and comprising at least one control valve (15). The present invention further relates to an assembly comprising said device, and to a method for providing a liquid medium with a controlled flow rate and with a controlled concentration in a dissolved gas.
    Type: Application
    Filed: September 30, 2021
    Publication date: January 4, 2024
    Applicants: Sorbonne Universite, Centre National De La Recherche Scientifique, Institut Curie, Fluigent
    Inventors: William Cesar, Charlotte Bouquerel, Marine Verhulsel, Jean-Louis Viovy, Stéphanie Descroix
  • Publication number: 20230303974
    Abstract: The present invention relates to an engineered immune cell defective for SOCS1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of SOCS1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.
    Type: Application
    Filed: July 30, 2021
    Publication date: September 28, 2023
    Applicants: Institut Curie, Institut National de la Santé et de la Recherche Médicale
    Inventors: Laurie Menger, Silvia Menegatti, Sebastian Amigorena
  • Publication number: 20230302050
    Abstract: The present application relates to fully humanized anti-FGFR4 single domain antibodies (sdAbs) and variants thereof. The present invention further relates to functionalized drug nanocarriers, nucleic acids, vectors, host cells, immune cells comprising said sdAbs, and compositions comprising thereof, as well as their use for therapy.
    Type: Application
    Filed: May 20, 2021
    Publication date: September 28, 2023
    Applicants: Institut Curie, Centre National de la Recherche Scientifique, The University of Zurich, Honing Biosciences
    Inventors: Sandrine Moutel, Franck Perez, Michele Bernasconi, Nagjie Laila Alijaj, Zélia Gouveia
  • Publication number: 20230293478
    Abstract: The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof: wherein W, X, Y and Z are as defined, for use in the treatment of Acute Myeloid Leukemia (AML).
    Type: Application
    Filed: May 12, 2021
    Publication date: September 21, 2023
    Applicants: Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Curie, Peter MacCallum Cancer Institute
    Inventors: Raphaël RODRIGUEZ, Mark DAWSON, Sylvain GARCIAZ, Tatiana CANEQUE COBO
  • Patent number: 11739073
    Abstract: A compound: wherein X1 represents an alkenylene group, a —NH—CO— group, a —CO—NH— group, Y1 represents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, X2 represents —O—, —CO—NH—, —NH—CO—NH—, —OCH2—, —NH—CO—, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or —SO2—NH—, and Y2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or —CR1R2R3 or alternatively X2—Y2 represents —CONRcRd, wherein Rc and Rd form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: August 29, 2023
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIE
    Inventors: Didier Scherrer, Jamal Tazi, Florence Mahuteau-Betzer, Romain Najman, Julien Santo, Cécile Apolit
  • Publication number: 20230218605
    Abstract: The present invention relates to an amorphous solid dispersion comprising ABX464 and at least one pharmaceutically acceptable carrier. The present invention also concerns a pharmaceutical composition comprising said ASD, processes for their preparation, an ASD obtainable by specific processes, their use as a medicament and more particularly their use in the treatment and/or prevention of inflammatory diseases, diseases caused by viruses and/or cancer or dysplasia.
    Type: Application
    Filed: January 29, 2021
    Publication date: July 13, 2023
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIE
    Inventors: Jérôme MENEGOTTO, Jérôme DENIS
  • Publication number: 20230220480
    Abstract: The invention relates to the use of an iron-score based on the expression level of at least 2 genes, in particular at least 5, preferably at least 10, and even preferably 11 genes selected in the group consisting of ALAS1, HIF1A, LRP2, HMOX1, HMOX2, HFE, ISCA1, SLC25A37, PPOX, STEAP1 and TMPRSS6 involved in the iron metabolism, as a prognosis marker in subjects having DLBCL, in particular for identifying subjects with a poor outcome such as a relapse and/or death.
    Type: Application
    Filed: November 6, 2020
    Publication date: July 13, 2023
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE DE MONTPELLIER, INSTITUT CURIE
    Inventors: Jérôme MOREAUX, Raphaël RODRIGUEZ, Julie DEVIN, Caroline BRET, Tatiana CANEQUE COBO
  • Publication number: 20230212243
    Abstract: The present application relates to a tumor specific neoantigenic peptide, wherein said peptide is encoded by a part of an ORF sequence from a transcript associated with a SF3B1 or a SF3B1-like mutation, comprises at least 8 amino acids and binds at least one MHC molecule with an affinity of less than 500 nM; and is not expressed in normal healthy cells. The present application further relates to vaccine or immunogenic composition, antibodies, T cell receptors, polynucleotides, vectors and immune cells derived thereof as well as their use in therapy of cancer.
    Type: Application
    Filed: May 12, 2021
    Publication date: July 6, 2023
    Applicants: Institut Curie, Institut National de la Santé et de la Recherche Médicale
    Inventors: Olivier Lantz, Marc-Henri Stern, Jérémy Bigot, Alexandre Houy, Ana Ines Lalanne
  • Publication number: 20230184775
    Abstract: The present invention concerns an ex vivo method for selecting patient having cancer as eligible to EGFR/RAS pathway inhibitor therapy, an EGFR/RAS pathway inhibitor for use for treating cancer in a patient, and a method for prognosis cancer outcome or progression.
    Type: Application
    Filed: May 11, 2021
    Publication date: June 15, 2023
    Applicant: INSTITUT CURIE
    Inventors: Keltouma Driouch, Rosette Lidereau
  • Publication number: 20230183675
    Abstract: The present invention relates to the identification of a fully humanized single domain antibody scaffold as well as its use in generating synthetic single domain antibodies. The invention further relates to antigen-binding proteins comprising said single domain antibody scaffold and their use in therapy.
    Type: Application
    Filed: May 20, 2021
    Publication date: June 15, 2023
    Applicants: Institut Curie, Centre National de la Recherche Scientifique
    Inventors: Franck Perez, Sandrine Moutel
  • Patent number: 11649211
    Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: May 16, 2023
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, Romain Najman, Florence Mahuteau, Didier Scherrer, Karim Chebli, Michael Hahne
  • Patent number: 11649210
    Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: May 16, 2023
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Didier Scherrer, Jamal Tazi, Florence Mahuteau, Romain Najman
  • Publication number: 20230117652
    Abstract: The invention relates to a method for detecting a mutation in a microsatellite sequence locus of a target fragment from a DNA sample, comprising subjecting said DNA sample to a digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising: a pair of primers for amplifying said target fragment of the DNA sample including said microsatellite sequence; a first MS oligonucleotide (MS) hydrolysis probe, labeled with a first fluorophore, wherein said first MS oligonucleotide probe is complementary to a wild-type sequence including the microsatellite sequence; and a second oligonucleotide reference (REF) hydrolysis probe, labeled with a second fluorophore, wherein said second oligonucleotide REF probe is complementary to a wild-type sequence of said target DNA fragment which does not include said microsatellite sequence. The invention also encompasses methods for the diagnosis and prognosis of cancer and a method for determining the efficacy of a cancer treatment.
    Type: Application
    Filed: September 21, 2022
    Publication date: April 20, 2023
    Applicants: Institut Curie, Institut National de la Sante et de la Recherche Medicale, Universite de Versailles Saint-Quentin-en-Yvelines
    Inventors: Charlotte Proudhon, Amélie Kasperek, Amanda Bortolini Silveira, François-Clément Bidard, Marc-Henri Stern
  • Patent number: 11622978
    Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.
    Type: Grant
    Filed: January 20, 2020
    Date of Patent: April 11, 2023
    Assignees: INSTITUT CURIE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Sebastian Amigorena, Eliane Piaggio, Christel Goudot, Luigia Pace, Genevieve Almouzni, Leticia Niborski
  • Publication number: 20230107291
    Abstract: The invention relates to a method of identification of functional disease-specific, in particular tumor-specific, regulatory T cells and markers thereof. The invention also relates to the derived functional tumor-specific regulatory T cells, markers and engineered regulatory T cells and to their use for the diagnosis, prognosis, monitoring and treatment of cancer.
    Type: Application
    Filed: February 22, 2021
    Publication date: April 6, 2023
    Applicants: Institut Curie, Institut National de la Santé et de la Recherche Médicale, Institut Mutualiste Montsouris
    Inventors: Eliane Piaggio, Wilfrid Richer, Christine Sedlik, Jimena Tosello, Joshua Waterfall, Elisa Bonnin
  • Publication number: 20230106420
    Abstract: A compound of formula (I) is: wherein: X2 represents a —CO—NRk— group, a —NR?k—CO— group, a —O— group, a —CO— group, a —SO2-group, a —CS—NH— group, a —CH2—NH—, a group, or a heterocyclyl, wherein the heterocyclyl is a 5- or 6-membered ring comprising 1, 2, 3 or 4 heteroatoms selected from O, S and/or N; Y2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a morpholinyl group, optionally substituted by a (C1-C4)alkyl group or a trifluoromethyl group, a bridged morpholinyl group, a (C5-C11)bicycloalkyl group, an adamantyl group, a piperidinyl group, a (C1-C4)alkenyl group, a —PO(ORa)(ORb) group, a 5-membered heteroaromatic ring or a —CR1R2R3 group, or any of its pharmaceutically acceptable salt.
    Type: Application
    Filed: July 17, 2020
    Publication date: April 6, 2023
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIE
    Inventors: Didier SCHERRER, Florence MAHUTEAU, Romain NAJMAN, Jamal TAZI, Julien SANTO, Cécile APOLIT, Frederic LABEGUERE, Brice SAUTIER, Natacha BIENVENU, Elisa AZZALI
  • Publication number: 20230067676
    Abstract: Co-crystals and pharmaceutically acceptable salts and methods for the preparation of the co-crystals and the pharmaceutically acceptable salts of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine, pharmaceutical compositions including them as well as their use as medicines and more particularly for use in the prevention and/or treatment of inflammatory diseases, diseases caused by viruses and/or cancer or dysplasia.
    Type: Application
    Filed: January 29, 2021
    Publication date: March 2, 2023
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIE
    Inventors: Jérôme MENEGOTTO, Jérôme DENIS